North Annette Acquires Turning Point Therapeutics Inc. (TPTX) Shares

Turning Point Therapeutics Inc. (NASDAQ:TPTX) finished Thursday with a subtraction of -$14.15 to close at $46.55, a downside of -23.31 percent. An average of 1,159,060 shares of common stock have been traded in the last five days. There was a fall of -$19.88 in the past week. The last 20 days have seen an average of 492,010 shares traded, while the 50-day average volume stands at 369,438.

TPTX stock has decreased by -40.45% in the last month. The company shares reached their 1-month lowest point of $42.51 on 10/07/21. With the stock rallying to its 52-week high on 02/08/21, shares of the company touched a low of $59.73 and a high of $141.30 in 52 weeks. In spite of this, the price is down -67.06% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


Insider Transactions

39 days have passed since Turning Point Therapeutics Inc. (TPTX) last reported insider trading activity. North Annette, who is EVP, General Counsel & Secty., most recently acquired $10,000 shares at $80.00 per share on Aug 30. In this transaction, the insider spent $800,000. EVP & Chief Commercial Officer, Partridge Andrew John, disposed of 1,869 shares at a price of $74.90 on Jul 14. The insider now owns more than $139,988 worth of shares. Prior to that, EVP, General Counsel & Secty. North Annette went on to Sale 15,000 shares at $77.03 each on Jun 15. An amount of $1,155,433 was transacted.

Valuation Metrics

Turning Point Therapeutics Inc. (TPTX) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.11 for the sector. This means investors are optimistic about the stock’s future prospects. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 40.96, the price-to-book (PB) ratio at 2.15.

The quick ratio of Turning Point Therapeutics Inc. for the three months ended June 29 was 34.20, and the current ratio was 34.20, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 For the recent quarter ending June 29. Turning Point Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -507.37%. Its gross profit as reported stood at $186.84 million compared to revenue of $25.0 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Turning Point Therapeutics Inc.’s return on assets was -15.30%. For the broader industry, ROE averaged -68.79 over the past year.

Earnings Surprise

For the three-month period that ended June 29, Turning Point Therapeutics Inc. had $651.76 million in cash. The analyst consensus anticipated Turning Point Therapeutics Inc.’s latest quarter earnings to come in at -$1.21 per share, but it turned out to be -$1.14, a 5.80% surprise. For the recent quarter, EBITDA amounted to -$54.44 million. Shareholders own equity worth $49.41 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Turning Point Therapeutics Inc. (TPTX) price momentum. RSI 9-day as of the close on 07 October was 8.78%, suggesting the stock is oversold, with historical volatility in this time frame at 117.37%.

As of today, TPTX’s price is $60.75 -29.93% or -$19.88 from its 5-day moving average. TPTX is currently trading -39.80% lower than its 20-day SMA and -33.92% lower than its 100-day SMA. However, the stock’s current price level is -28.89% below the SMA50 and -64.45% below the SMA200.

The stochastic %K and %D were 4.70% and 6.09%, respectively, and the average true range (ATR) was 5.35. With the 14-day stochastic at 10.29% and the average true range at 4.66, the RSI (14) stands at 15.97%. The stock has reached -8.10 on the 9-day MACD Oscillator while the 14-day reading was at -12.62.

Analyst Ratings

Stifel launched coverage on Turning Point Therapeutics Inc. (NASDAQ: TPTX) in its analyst report released on September 30, 2021. The firm assigned the stock a a Hold rating.The consensus rating for Turning Point Therapeutics Inc. (TPTX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TPTX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 10 others rate it as a “buy”.

What is TPTX’s price target for the next 12 months?

Analysts predict a range of price targets between $75.00 and $178.00, with a median target of $143.00. Taking a look at these predictions, the average price target given by analysts for Turning Point Therapeutics Inc. (TPTX) stock is $138.00.


Please enter your comment!
Please enter your name here


Hot Topics

Related Videos

Related Videos

Related Articles



Download Free eBook For



100% free. stop anytime no spam